Immune checkpoint inhibitors and neuromuscular adverse events

Medicine & Life Sciences

• Autoantibodies 37%
• Central Nervous System Diseases 44%
• Disease Progression 32%
• Dizziness 42%
• Dysgeusia 62%
• Guidelines 26%
• Hashimoto's encephalitis 60%
• Headache 35%
• Muscles 24%
• Myocarditis 46%
• Myositis 100%
• Neoplasms 39%
• Neuromuscular Junction 47%
• Peripheral Nerves 39%
• Pharmaceutical Preparations 16%
• Polyneuropathies 48%
• T-Lymphocytes 25%
• Therapeutics 33%